Mark E. Newman's most recent trade in Chemours Company was a trade of 7,661 Common Stock done at an average price of $32.6 . Disclosure was reported to the exchange on June 9, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Chemours Company | Mark E. Newman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 32.63 per share. | 09 Jun 2023 | 7,661 | 266,954 (0%) | 0% | 32.6 | 249,978 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 100,200 | 100,200 | - | - | Performance Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 147,540 | 292,224 (0%) | 0% | 0 | Common Stock | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.35 per share. | 10 Feb 2023 | 70,974 | 221,250 (0%) | 0% | 34.4 | 2,437,957 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.22 per share. | 05 May 2022 | 197,161 | 176,347 (0%) | 0% | 40.2 | 7,929,815 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.04 per share. | 05 May 2022 | 197,161 | 373,508 (0%) | 0% | 16.0 | 3,162,462 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 197,161 | 0 | - | - | Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 206,268 | 206,268 | - | - | Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 19,630 | 176,253 (0%) | 0% | 0 | Common Stock | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.98 per share. | 01 Mar 2022 | 1,253 | 156,623 (0%) | 0% | 26.0 | 32,553 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 19,473 | 165,010 (0%) | 0% | 0 | Common Stock | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.00 per share. | 11 Feb 2022 | 7,133 | 157,877 (0%) | 0% | 30 | 213,990 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2021 | 34,252 | 0 | - | - | Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.45 per share. | 02 Dec 2021 | 34,252 | 179,710 (0%) | 0% | 18.4 | 631,949 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 29.94 per share. | 02 Dec 2021 | 34,252 | 145,458 (0%) | 0% | 29.9 | 1,025,505 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 3,691 | 34,252 | - | - | Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 30 Aug 2021 | 3,691 | 145,377 (0%) | 0% | 35 | 129,185 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.45 per share. | 30 Aug 2021 | 3,691 | 149,068 (0%) | 0% | 18.5 | 68,099 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2021 | 29,732 | 37,943 | - | - | Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 27 Aug 2021 | 29,732 | 145,377 (0%) | 0% | 35 | 1,040,620 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.45 per share. | 27 Aug 2021 | 29,732 | 175,109 (0%) | 0% | 18.4 | 548,555 | Common Stock |
| Chemours Company | Mark E. Newman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 34,696 | 34,696 | - | - | Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 3,948 | 145,377 (0%) | 0% | 0 | Common Stock | |
| Altria Group | Mark E. Newman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 3,517 | 22,604 (0%) | 0% | 0 | Common Stock | |
| Chemours Company | Mark E. Newman | Senior VP & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 61,349 | 61,349 | - | - | Stock Option (Right to Buy) | |
| Chemours Company | Mark E. Newman | Senior VP & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 6,247 | 141,271 (0%) | 0% | 0 | Common Stock | |
| Chemours Company | Mark E. Newman | Senior VP & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 2,868 | 136,212 (0%) | 0% | 0 | Common Stock | |
| Chemours Company | Mark E. Newman | Senior VP & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.14 per share. | 12 Feb 2021 | 1,188 | 135,024 (0%) | 0% | 26.1 | 31,054 | Common Stock |